everolimus — CareFirst (Caremark)
TSC-associated renal angiomyolipoma
Initial criteria
- Used for treatment of TSC or its associated manifestations
Reauthorization criteria
- Continuation may be approved when no unacceptable toxicity or disease progression
Approval duration
12 months